The role of human and viral cytokines in the pathogenesis of multiple myeloma

Seminars in Cancer Biology

Volumn 10, Issue 5, 2000, Pages 383-391

  Berenson, James R ^a,b   Sjak Shie, Nelida N ^a,b   Vescio, Robert A ^a,b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cytokines; HHV 8; Multiple myeloma

Indexed keywords

CYTOKINE;

ANEMIA; B LYMPHOCYTE; BONE DESTRUCTION; CYTOKINE RELEASE; DISEASE ASSOCIATION; HUMAN HERPESVIRUS 8; KIDNEY FAILURE; MULTIPLE MYELOMA; PATHOGENESIS; REVIEW; STROMA CELL;

EID: 0033767858     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1006/scbi.2000.0332     Document Type: Article

References (92)

1. Interleukin-6 in human multiple myeloma
2. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma
3. Defective development of pristane-oil-induced plasmacytomas in interleukin-6 deficient BALB/c mice
4. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma
5. High levels of interleukin-6 are associated with low tumor burden and low growth fraction in multiple myeloma
6. Interleukin-6 serum levels in patients with multiple myeloma
7. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6
8. Interleukin-6 inhibits apoptosis of malignant plasma cells
9. Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells
10. Prevention of myeloma cell apoptosis by ectopic bcl-2 expression or interleukin 6-mediated up-regulation of bcl-χ(L)
11. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells
12. Signal transduction of interleukin-6 involves tyrosine phosphorylation of multiple cytosolic proteins and activation of Src-family kinases Fyn, Hck, and Lyn in multiple myeloma cell lines
13. Interleukin-6 inhibits bone formation in vitro
14. Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors
15. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6
16. Autocrine generation and essential requirement of BSF-2/IL-6 for human multiple myeloma
17. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion
18. Evidence for bidirectional interactions between osteoclasts and myeloma cells
19. Human myeloma cells promote the production of interleukin 6 by primary human osteoblasts
20. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-κ B
21. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma
22. Major role of the soluble interleukin-6/interleukin-6 receptor complex for the proliferation of interleukin-6-dependent human myeloma cell lines
23. The prognostic value of soluble interleukin-6 receptor in patients with multiple myeloma
24. Production of cytokines by bone marrow cells obtained from patients with multiple myeloma
25. Production of interleukin-1 by bone marrow myeloma cells
26. Comparison of interleukin-1β expression in in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma
27. Lack of IL-1 secretion from human myeloma cells highly purified by immunomagnetic separation
28. Interleukin-1 in multiple myeloma: Producer cells and their role in the control of IL-6 production
29. Biologic basis for interleukin-1 in disease
30. Production of interleukin 1β, a potent bone resorbing cytokine, by cultured human myeloma cells
31. Modulaton of osteoclast-activating factor activity of multiple myeloma bone marrow cells by different interleukin-1 inhibitors
32. Association between ICAM-1 expression and metastatic capacity of murine B-cell hybridomas
33. Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells
34. Expression of interleukin-1β and tumour necrosis factor-α in plasma cells from patients with multiple myeloma
35. Growth regulatory pathways in myeloma: Evidence for autocrine oncostatin M expression
36. Oncostatin M induces association of Grb2 with Janus Kinase JAK2 in multiple myeloma cells
37. Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop
38. Interleukin-10 induces interleukin-11 responsiveness in human myeloma cell lines
39. Osteoclast differentiation factor is a lig- and for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
40. Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: A possible role for HGF in myeloma-associated osteolytic bone disease
41. Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma
42. Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma
43. Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines
44. Multiple myeloma cells are protected against dexamethasone-induced apoptosis by insulin-like growth factors
45. Potential role of insulin-like growth factor binding protein-4 in the uncoupling of bone turnover in multiple myeloma
46. Bone marrow angiogenesis and progression in multiple myeloma
47. Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption
48. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo
49. Antitumor activity of thalidomide in refractory multiple myeloma
50. Transforming growth factor-β1: Differential effects on multiple myeloma versus normal B cells
51. Serum transforming growth factor-β1 is related to the degree of immunoparesis in patients with multiple myeloma
52. Consistent loss of functional transforming growth factor beta receptor expression in murine plasmacytomas
53. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma
54. Strain variability among Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genomes: Evidence that a large cohort of United States AIDS patients may have been infected by a single common isolate
55. Comparison of genetic variability at multiple loci across the genomes of the major subtypes of Kaposi's sarcoma-associated herpesvirus reveals evidence for recombination and for two distinct types of open reading frame K15 alleles at the right-hand end
56. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8)
57. Cell-homologous genes in the Kaposi's sarcoma-associated rhadinovirus human herpesvirus 8: Determinants of its pathogenicity?
58. Kaposi's sarcoma-associated herpesvirus contains G protein-coupled receptor and cyclin D homologs which are expressed in Kaposi's sarcoma and malignant lymphoma
59. Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV
60. A Bcl-2 homolog encoded by Kaposi sarcoma-associated virus, human herpesvirus 8, inhibits apoptosis but does not heterodimerize with Bax or Bak
61. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors
62. Kaposi's sarcoma-associated human herpesvirus-8 encodes homologues of macrophage inflammatory protein-1 and interleukin-6
63. KSHV-encoded CC chemokine vMIP-III is a CCR4 agonist, stimulates angiogenesis, and selectively chemoattracts TH2 cells
64. Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients
65. Localization of Kaposi's sarcoma-associated herpesvirus in bone marrow biopsy samples from patients with multiple myeloma
66. Human herpesvirus type 8 interleukin-6 homologue is functionally active on human myeloma cells
67. Spectrum of AIDS-associated malignant disorders
68. Human herpesvirus 8 (KSHV) contamination of peripheral blood and autograft products from multiple myeloma patients
69. Kaposi's sarcoma-associated herpesvirus infection and multiple myeloma
70. Dendritic cells cultured from mononuclear cells and CD34 cells in myeloma do not harbour human herpesvirus 8
71. HHV-8 and multiple myeloma in the UK
72. HHV-8 and multiple myeloma in France
73. Kaposi's sarcoma-associated herpesvirus infection and multiple myeloma
74. Kaposi's sarcoma-associated herpesvirus infection and multiple myeloma
75. Kaposi's sarcoma-associated herpesvirus infection and multiple myeloma
76. Detection of human herpesvirus-8 DNA in bone marrow biopsies from patients with, multiple myeloma and Waldenstrom's macroglobulinemia
77. Frequent demonstration of human herpesvirus 8 (HHV-8) in bone marrow biopsy samples from Turkish patients with multiple myeloma (MM)
78. Kaposi's sarcoma-associated herpesvirus infection and multiple myeloma
79. Detection of Kaposi's sarcoma herpesvirus DNA sequences in multiple myeloma bone marrow stromal cells
80. Detection of human herpesvirus-8 in Greek patients with multiple myeloma and monoclonal gammopathy of undetermined significance
81. The role of human herpesvirus-8 in the pathogenesis of multiple myeloma
82. Lack of evidence of any association between human herpesvirus 8 and various skin tumors from both immunocompetent and immunosuppressed patients
83. Antibodies to Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in patients with multiple myeloma
84. Identification of the gene encoding the major latency-associated nuclear antigen of the Kaposi's sarcoma-associated herpesvirus
85. Comparative analysis of Epstein-Barr virus gene polymorphisms in nasal T/NK-cell lymphomas and normal nasal tissues: Implications on virus strain selection in malignancy
86. Distinct biology of Kaposi's sarcoma-associated herpesvirus from primary lesions and body cavity lymphomas
87. Study of human herpesvirus 8 (HHV-8) variants from Kaposi's sarcoma in France: Is HHV-8 subtype A responsible for more aggressive tumors
88. KSHV ORF K9 (vIRF) is an oncogene which inhibits the interferon signaling pathway
89. C-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator
90. Vascular endothelial growth factor and angiogenesis in multiple myeloma